Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.540
+0.150 (10.79%)
At close: Jul 3, 2025, 1:00 PM
1.452
-0.088 (-5.74%)
After-hours: Jul 3, 2025, 4:53 PM EDT
Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc.
| Country | Canada |
| Founded | 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 18 |
| CEO | David Elsley |
Contact Details
Address: 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5 Canada | |
| Phone | 289 910 0850 |
| Website | cardiolrx.com |
Stock Details
| Ticker Symbol | CRDL |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001702123 |
| CUSIP Number | 14161Y200 |
| ISIN Number | CA14161Y2006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David G. Elsley MBA | President, Chief Executive Officer and Director |
| Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | Chief Financial Officer, Corporate Secretary and Director |
| Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research and Development |
| Trevor Burns | Investor Relations |
| John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 14, 2025 | 6-K | Report of foreign issuer |
| Apr 29, 2025 | 6-K | Report of foreign issuer |
| Apr 28, 2025 | 6-K | Report of foreign issuer |
| Apr 16, 2025 | 6-K | Report of foreign issuer |
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 40-F | Filing |
| Mar 14, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |